Display options
Cite
Bae JC. Diabetes Drugs and Cardiovascular Safety. Endocrinol Metab (Seoul). 2016;31(2):239-44doi: 10.3803/EnM.2016.31.2.239.
Bae, J. C. (2016). Diabetes Drugs and Cardiovascular Safety. Endocrinology and metabolism (Seoul, Korea), 31(2), 239-44. https://doi.org/10.3803/EnM.2016.31.2.239
Bae, Ji Cheol. "Diabetes Drugs and Cardiovascular Safety." Endocrinology and metabolism (Seoul, Korea) vol. 31,2 (2016): 239-44. doi: https://doi.org/10.3803/EnM.2016.31.2.239
Bae JC. Diabetes Drugs and Cardiovascular Safety. Endocrinol Metab (Seoul). 2016 Jun;31(2):239-44. doi: 10.3803/EnM.2016.31.2.239. Epub 2016 Jun 10. PMID: 27302713; PMCID: PMC4923407.
Copy Download .nbib Format: NLM
Share it on

Endocrinol Metab (Seoul). 2016 Jun;31(2):239-44. doi: 10.3803/EnM.2016.31.2.239. Epub 2016 Jun 10.

Diabetes Drugs and Cardiovascular Safety.

Endocrinology and metabolism (Seoul, Korea)

Ji Cheol Bae

Affiliations

  1. Division of Endocrinology and Metabolism, Department of Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea. [email protected].

PMID: 27302713 PMCID: PMC4923407 DOI: 10.3803/EnM.2016.31.2.239

Abstract

Diabetes is a well-known risk factor of cardiovascular morbidity and mortality, and the beneficial effect of improved glycemic control on cardiovascular complications has been well established. However, the rosiglitazone experience aroused awareness of potential cardiovascular risk associated with diabetes drugs and prompted the U.S. Food and Drug Administration to issue new guidelines about cardiovascular risk. Through postmarketing cardiovascular safety trials, some drugs demonstrated cardiovascular benefits, while some antidiabetic drugs raised concern about a possible increased cardiovascular risk associated with drug use. With the development of new classes of drugs, treatment options became wider and the complexity of glycemic management in type 2 diabetes has increased. When choosing the appropriate treatment strategy for patients with type 2 diabetes at high cardiovascular risk, not only the glucose-lowering effects, but also overall benefits and risks for cardiovascular disease should be taken into consideration.

Keywords: Cardiovascular diseases; Diabetes mellitus; Heart failure; Hypoglycemic agents

References

  1. Lancet. 2005 Oct 8;366(9493):1279-89 - PubMed
  2. N Engl J Med. 2007 Jun 14;356(24):2457-71 - PubMed
  3. Ann Intern Med. 2007 Oct 16;147(8):578-81 - PubMed
  4. Diabetes Care. 2007 Sep;30(9):2401-8 - PubMed
  5. JAMA. 2007 Sep 12;298(10):1180-8 - PubMed
  6. JAMA. 2007 Sep 12;298(10):1189-95 - PubMed
  7. Lancet. 2007 Sep 29;370(9593):1129-36 - PubMed
  8. N Engl J Med. 2008 Oct 9;359(15):1577-89 - PubMed
  9. N Engl J Med. 2008 Sep 11;359(11):1092-5 - PubMed
  10. Lancet. 2009 Jun 20;373(9681):2125-35 - PubMed
  11. Diabetologia. 2009 Nov;52(11):2288-98 - PubMed
  12. Diabetes Care. 2009 Nov;32 Suppl 2:S223-31 - PubMed
  13. JAMA. 2010 Jul 28;304(4):411-8 - PubMed
  14. Arch Intern Med. 2010 Jul 26;170(14):1191-1201 - PubMed
  15. N Engl J Med. 2010 Oct 14;363(16):1489-91 - PubMed
  16. Rev Diabet Stud. 2011 Fall;8(3):323-38 - PubMed
  17. Diabetes Care. 2012 Jun;35(6):1364-79 - PubMed
  18. Diab Vasc Dis Res. 2013 Jul;10(4):289-301 - PubMed
  19. Diabetes Care. 2013 Jul;36(7):2098-106 - PubMed
  20. Circulation. 2013 Aug 20;128(8):785-94 - PubMed
  21. N Engl J Med. 2013 Oct 3;369(14):1317-26 - PubMed
  22. N Engl J Med. 2013 Oct 3;369(14):1327-35 - PubMed
  23. N Engl J Med. 2014 Jan 30;370(5):483 - PubMed
  24. Cardiovasc Ther. 2014 Aug;32(4):147-58 - PubMed
  25. Circulation. 2014 Jun 24;129(25):2705-13 - PubMed
  26. JACC Heart Fail. 2014 Dec;2(6):583-5 - PubMed
  27. Lancet. 2014 Nov 29;384(9958):1936-41 - PubMed
  28. Circulation. 2014 Oct 28;130(18):1565-7 - PubMed
  29. Circulation. 2014 Oct 28;130(18):1579-88 - PubMed
  30. Clin Ther. 2014 Dec 1;36(12):2072-2079 - PubMed
  31. Diab Vasc Dis Res. 2015 Mar;12(2):90-100 - PubMed
  32. Lancet. 2015 May 23;385(9982):2022-4 - PubMed
  33. Lancet Diabetes Endocrinol. 2015 May;3(5):356-66 - PubMed
  34. N Engl J Med. 2015 Jun 4;372(23):2197-206 - PubMed
  35. N Engl J Med. 2015 Jul 16;373(3):232-42 - PubMed
  36. N Engl J Med. 2015 Nov 26;373(22):2117-28 - PubMed
  37. N Engl J Med. 2015 Dec 3;373(23):2247-57 - PubMed
  38. Kidney Int. 2016 Mar;89(3):524-6 - PubMed
  39. N Engl J Med. 2016 Apr 7;374(14):1321-31 - PubMed
  40. JAMA Cardiol. 2016 May 1;1(2):126-35 - PubMed

Publication Types